Close this search box.
    • Small Molecules
      • Discovery
    • Biologics
    • Other Drug Modalities
    • SynVent Integrated Drug Discovery
      • SynVent Integrated Drug Discovery

        SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules. 

    • Industries
    • Emerging Biopharma
      • Emerging Biopharma

        Emerging biopharma work at the forefront of science, often venturing into disease areas where little or no real-world data exists to work with or regulatory frameworks to work within.

    • Dedicated Centers
      • Dedicated Centers

        Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their  R&D  goals

    • Center for Advanced Protein Studies (CAPS)
      • Center for Advanced Protein Studies (CAPS)

        Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.

  • Careers
Close this search box.

White Papers

Choose from a variety of resources to get a better understanding of Syngene’s point of view, expertise or approach to drug discovery, development and manufacturing to ensure client success.

How to overcome solubility challenges by applying amorphous solid dispersion: An end-to-end solution

Discover the successful approach to preparing, screening, characterizing, and dosing amorphous solid dispersions (ASDs) in preclinical and early clinical development.

Cracking the Code: Transformative role of pDNA in advanced modalities

Reasons behind the rise in demand for pDNA and what to look for in a pDNA engineering and manufacturing partner when deciding to outsource.

Pharma Supply Chain: From Fragile to Agile

CDMOs bolster supply networks with additional capabilities to make themselves resilient to potential challenges and ensure secure supplies to customers.

Quality management paradigm shift: Risk-centric practices come center stage

CDMOs have moved to risk-based quality management systems comprising highly integrated and digitalized processes powered by data to ensure drug quality.

Protein therapeutics to amp up outsourcing in animal health

With the boom in pet ownership and rising awareness about pet health, veterinary drug makers are betting big on protein therapeutics and outsourcing biologics development to CDMOs.

CROs at the high table of drug discovery

Find out how offshoring has reached an inflection point as CROs turn risk-sharing partners in discovery research.

CMOs bask in pill promise

With sponsors having more oral solid dosage (OSD) products in their pipelines, CMOs anticipate an increasing trend in OSD outsourcing. Find out the criteria to choose the right CMO for OSD outsourcing.

Pharma 4.0: Taking CDMO factories by storm

Contract development manufacturing firms are ramping up the adoption of Pharma 4.0 technologies as regulators and customers increasingly seek transparency and integrity in manufacturing data.

New modalities hog the limelight

Explore how Cell and Gene, mRNA, Bispecifics, and ADCs are turning the tide as CDMOs see service demand for these therapies soar.

Bioanalytical outsourcing soars as drugs grow more complex

Outsourcing of bioanalytical lab services is set for explosive growth as the increasingly complex nature of modern-day therapeutics makes partnerships with CROs indispensable.

Your browser does not support this function.

To download, Please share your details

This Website uses Cookies

We use cookies to improve your experience on our site and show you information relevant to your requirements. To find out more, read our Privacy Policy and Cookies Policy.

To view or email, Please share your details view

To download, Please share your details